2024-11-14
Biostar to collaborate with Baheal Medical to accelerate the commercialization process of Utidelone
news
-
-
2024-10-31Beijing Biostar successfully landed on the main board of the Hong Kong Stock Exchange, synthetic biology leads the new era of innovative drug research and development
-
2024-09-30Preliminary data released from a clinical study of Utidelone for the first-line treatment of advanced pancreatic cancer
-
2024-09-03Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
-
2024-07-05Biostar Pharma Announces FDA Clearance of the IND Application for a Phase 2 Study of Utidelone Injection (UTD1) in HER2- Breast Cancer Brain Metastasis
-
2024-03-2873% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
-
2024-03-21100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
-
2023-06-16FDA Approved Utidelone Injectable (UTD1) Phase 2/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer
-
2023-06-12Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)—The World's First Oral Epothilone Anti-Cancer Drug